Assessing skin cancer risk in patients with Epidermolysis Bullosa using Filsuvez

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with Epidermolysis Bullosa (EB), a condition that leads to fragile skin and a higher risk of skin cancers. Participants with dystrophic EB or junctional EB will receive standard care, which may include the topical gel Filsuvez, and will be monitored for up to five years. The study aims to determine if the use of Filsuvez influences the incidence of skin malignancies such as squamous cell carcinoma, basal cell carcinoma, and malignant melanoma. Data will be collected from clinical centers in the EU and UK, as well as existing EB registries.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a confirmed diagnosis of dystrophic EB or junctional EB

Exclusion Criteria:

* None

Where it's running

• CHU de Toulouse, Hôpital Larrey
  Toulouse, France Recruiting
• UMC Freiburg EB Centre
  Freiburg im Breisgau, Germany Recruiting
• Hospital of Skin and Venereal Diseases of Thessaloniki
  Thessaloniki, Greece Recruiting
• Hospital Clinic, Barcelona
  Barcelona, Spain Recruiting
• Hospital San Juan de Dios (Barcelona)
  Barcelona, Spain Recruiting
• Guy's and St Thomas' NHS Foundation Trust
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Chiesi Clinical Trials
• Email: clinicaltrials_info@chiesi.com
• Phone: +3905212791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oleogel-S10 gel for healing skin wounds in Japanese patients with epidermolysis bullosa.

  We will try Oleogel‑S10 gel to see if it closes or shrinks wounds in Japanese children and adults with junctional or dystrophic epidermolysis bullosa.

  Recruiting at 6 sites Phase 3 Chiesi Farmaceutici S.p.A. · Fukuoka and 5 other locations · NCT06917690

• Energy-F703EB Cream for Epidermolysis Bullosa: a skin cream test in adults

  This phase 2 study tests ENERGI-F703EB Cream versus a matching vehicle to see if it is safe and helps small EB skin lesions in adults.

  Recruiting Phase 2 Energenesis Biomedical Co., Ltd. · Tainan · NCT07858422

• Ev.FV to heal wounds in dystrophic epidermolysis bullosa

  This trial will test whether Ev.FV, a mesenchymal stem cell-derived extracellular vesicle therapy, helps heal wounds in people with dystrophic epidermolysis bullosa.

  Recruiting Phase 1/2 Isfahan University of Medical Sciences · Isfahan · NCT07230223

• KB803 eye drops versus placebo for people with dystrophic epidermolysis bullosa

  This trial tests whether KB803 eye drops, given three times a week, can reduce recurrent corneal abrasions in children and adults with dystrophic epidermolysis bullosa.

  Recruiting at 5 sites Phase 3 Krystal Biotech, Inc. · Rancho Santa Margarita, California and 4 other locations · NCT07016750

• Using IV immunoglobulin to lower collagen VII antibodies in dystrophic epidermolysis bullosa

  This trial tests whether IV immunoglobulin given to people with recessive dystrophic epidermolysis bullosa who are on VYJUVEK helps wounds heal faster and lowers collagen VII and HSV‑1 antibody levels.

  Recruiting Phase 1/2 Stanford University · Redwood City, California · NCT06834035

• Topical TCP-25 gel to help heal wounds in epidermolysis bullosa

  This trial tests whether applying TCP-25 gel to matched skin wounds helps improve healing in children and adults with dystrophic or junctional epidermolysis bullosa.

  Recruiting at 12 sites Phase 2 Xinnate AB · Cincinnati, Ohio and 12 other locations · NCT06594393

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.